Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study). - Nagai SE; Hattori M; Yoshinami T; Masuda H; Okamura T; Watanabe K; Nakayama T; Tsuneizumi M; Takabatake D; Harao M; Yoshino H; Mori N; et al. (Breast cancer (Tokyo, Japan), 2026)